School of Medicine
Showing 1-7 of 7 Results
Clinical Assistant Professor, Medicine - Hematology
Bio Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Health Research and Policy (Epidemiology)
Current Research and Scholarly Interests We are interested in the link between metabolic disturbances, such as obesity and insulin resistance, and the development of cardiovascular disease. Our research is translational and interdisciplinary, combining population-based studies with molecular biology to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel drug targets.
John P.A. Ioannidis
C. F. Rehnborg Professor in Disease Prevention in the School of Medicine, Professor of Medicine, of Health Research and Policy (Epidemiology) and by courtesy, of Statistics and of Biomedical Data Science
Current Research and Scholarly Interests Meta-research
Clinical and molecular epidemiology
Human genome epidemiology
Reporting of research
Empirical evaluation of bias in research
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science
Clinical Associate Professor, Medicine - Primary Care and Population Health
Bio Dr. Ip is Director of Clinical Therapeutics Curriculum for the Stanford University MSPA Program and Clinical Associate Professor in the Department of Medicine, Division of Primary Care and Population Health. He completed his Doctor of Pharmacy degree from UCSF School of Pharmacy and his post-graduate residency at Kaiser Permanente Santa Clara Medical Center. He is a clinical pharmacist specializing in diabetes and cardiovascular care. He established and currently co-leads the Diabetes Management Program at Kaiser Permanente Mountain View Medical Offices. He is also Chair and Professor of Clinical Sciences at Touro University California College of Pharmacy. Dr. Ip's research interests include anabolic steroids and performancing enhancing drugs as well as educational research.
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Bio I am an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine and practicing oncologist at the Stanford Cancer Center with background in biomedical informatics. As a physician-scientist, my research mission is to drive medical advances at the intersection of cancer and data science research. Specifically, I aim to innovate state-of-the-art technologies to extract clinically useful knowledge from heterogeneous multi-scale biomedical data to improve diagnostics and therapeutics in cancer. I am a board-certified hematologist-oncologist and informaticist with specialized training in basic science, health services, and translational research. My clinical background in oncology and PhD training in Biomedical Informatics position me to develop and apply data science methodologies on heterogeneous, multi-scale cancer to extract actionable knowledge that can improve outcomes in cancer. My ongoing research to develop and apply cutting-edge knowledge and skills to pioneer new robust methodologies for analyzing cancer big data is being supported by an NIH K01 Career Development Award in Biomedical Big Data Science. My research focuses on developing and applying machine learning frameworks and radiogenomic approaches for the integrative analysis of heterogeneous, multi-scale data to accelerate discoveries in cancer diagnostics and therapeutics. Projects include prediction modeling of survival and treatment response, biomarker discovery, cancer subtype discovery, and identification of new therapeutic targets.